Prescient Therapeutics (ASX:PTX) Total Equity : A$22.61 Mil (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Prescient Therapeutics Total Equity?

Prescient Therapeutics's total equity for the quarter that ended in Dec. 2023 was A$22.61 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Prescient Therapeutics Total Equity Historical Data

The historical data trend for Prescient Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics Total Equity Chart

Prescient Therapeutics Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Equity

Get a 7-Day Free Trial

14.32

11.19

20.43

16.76

26.08

Prescient Therapeutics Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Equity	Get a 7-Day Free Trial															18.63	16.76	24.80	26.08	22.61

Prescient Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Prescient Therapeutics's Total Equity for the fiscal year that ended in Jun. 2023 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2023 )	-	Total Liabilities(Q: Jun. 2023 )
	=	28.108	-	2.033
	=	26.08

Prescient Therapeutics's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	24.762	-	2.152
	=	22.61

Prescient Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (ASX:PTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (ASX:PTX) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205

Website

https://www.ptxtherapeutics.com

Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (ASX:PTX) Headlines

No Headlines